SG185746A1 - Treatment of autoimmune diseases - Google Patents

Treatment of autoimmune diseases Download PDF

Info

Publication number
SG185746A1
SG185746A1 SG2012086526A SG2012086526A SG185746A1 SG 185746 A1 SG185746 A1 SG 185746A1 SG 2012086526 A SG2012086526 A SG 2012086526A SG 2012086526 A SG2012086526 A SG 2012086526A SG 185746 A1 SG185746 A1 SG 185746A1
Authority
SG
Singapore
Prior art keywords
halogen
compound
formula
phenyl
prodrug
Prior art date
Application number
SG2012086526A
Other languages
English (en)
Inventor
Peter Gergely
Erik Wallstroem
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42199281&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG185746(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SG185746A1 publication Critical patent/SG185746A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/661Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C321/00Thiols, sulfides, hydropolysulfides or polysulfides
    • C07C321/24Thiols, sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
    • C07C321/28Sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
    • C07C321/30Sulfides having the sulfur atom of at least one thio group bound to two carbon atoms of six-membered aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SG2012086526A 2010-05-06 2011-05-05 Treatment of autoimmune diseases SG185746A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10162079 2010-05-06
PCT/EP2011/057203 WO2011138393A1 (en) 2010-05-06 2011-05-05 Treatment of autoimmune diseases

Publications (1)

Publication Number Publication Date
SG185746A1 true SG185746A1 (en) 2013-01-30

Family

ID=42199281

Family Applications (1)

Application Number Title Priority Date Filing Date
SG2012086526A SG185746A1 (en) 2010-05-06 2011-05-05 Treatment of autoimmune diseases

Country Status (24)

Country Link
US (1) US20130172297A1 (https=)
EP (1) EP2566470A1 (https=)
JP (1) JP2013530937A (https=)
KR (1) KR20130066630A (https=)
CN (1) CN102869353A (https=)
AU (1) AU2011249784B2 (https=)
BR (1) BR112012028190A2 (https=)
CA (1) CA2795394A1 (https=)
CL (1) CL2012003091A1 (https=)
CR (1) CR20120566A (https=)
CU (1) CU20120154A7 (https=)
EA (1) EA201201514A1 (https=)
EC (1) ECSP12012312A (https=)
IL (1) IL222690A0 (https=)
MA (1) MA34285B1 (https=)
MX (1) MX2012012926A (https=)
NZ (1) NZ603999A (https=)
PE (1) PE20130612A1 (https=)
PH (1) PH12012502418A1 (https=)
SG (1) SG185746A1 (https=)
TN (1) TN2012000509A1 (https=)
TW (1) TW201201814A (https=)
WO (1) WO2011138393A1 (https=)
ZA (1) ZA201207710B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI519539B (zh) * 2010-12-21 2016-02-01 Kyorin Seiyaku Kk Diphenyl sulfide derivatives and pharmaceuticals as an active ingredient thereof
US9289494B2 (en) 2013-11-20 2016-03-22 RestorTears, LLC Method of treating ocular disorders with compounds found in Harderian gland secretions

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1431275B1 (en) * 2001-09-27 2010-04-07 Kyorin Pharmaceutical Co., Ltd. Diaryl ether derivative, addition salt thereof, and immunosuppressant
MXPA04002679A (es) * 2001-09-27 2004-07-30 Kyorin Seiyaku Kk Derivados de sulfuro de diarilo, sales de los mismos y agentes inmunosupresores que utilizan los mismos.
KR101003877B1 (ko) 2002-09-19 2010-12-30 교린 세이야꾸 가부시키 가이샤 아미노알코올 유도체와 그 부가염 및 면역 억제제
US7456157B2 (en) 2003-02-18 2008-11-25 Kyorin Pharmaceutical Co., Ltd. Aminophosphonic acid derivatives, addition salts thereof and S1P receptor modulators
JP4716996B2 (ja) * 2003-05-26 2011-07-06 武田薬品工業株式会社 スルホピロール
CN1874996B (zh) 2003-08-28 2011-05-18 诺瓦提斯公司 氨基丙醇衍生物
EP1723138B1 (en) * 2004-02-11 2010-07-14 Basilea Pharmaceutica AG Substituted benzimidazoles and their use for inducing apoptosis
WO2006041015A1 (ja) * 2004-10-12 2006-04-20 Kyorin Pharmaceutical Co., Ltd. アミノアルコール誘導体とその付加塩及び免疫抑制剤
GB0504544D0 (en) * 2005-03-04 2005-04-13 Novartis Ag Organic compounds
SI2295049T1 (sl) * 2005-09-09 2015-03-31 Novartis Ag Zdravljenje avtoimunskih bolezni

Also Published As

Publication number Publication date
CU20120154A7 (es) 2013-03-27
CR20120566A (es) 2013-01-09
PH12012502418A1 (en) 2018-03-21
BR112012028190A2 (pt) 2016-08-02
IL222690A0 (en) 2012-12-31
MX2012012926A (es) 2012-12-17
KR20130066630A (ko) 2013-06-20
ECSP12012312A (es) 2012-12-28
CA2795394A1 (en) 2011-11-10
NZ603999A (en) 2014-06-27
PE20130612A1 (es) 2013-06-06
TN2012000509A1 (en) 2014-04-01
US20130172297A1 (en) 2013-07-04
EA201201514A1 (ru) 2013-05-30
CN102869353A (zh) 2013-01-09
MA34285B1 (fr) 2013-06-01
AU2011249784B2 (en) 2014-03-06
WO2011138393A1 (en) 2011-11-10
AU2011249784A1 (en) 2012-12-20
JP2013530937A (ja) 2013-08-01
ZA201207710B (en) 2013-06-26
CL2012003091A1 (es) 2013-03-22
TW201201814A (en) 2012-01-16
EP2566470A1 (en) 2013-03-13

Similar Documents

Publication Publication Date Title
US7825260B2 (en) Aminopropanol derivatives as sphingosine-1-phosphate receptor modulators
US8008286B2 (en) Method for treatment of neuropathic pain
TWI592391B (zh) 用於合成及使用造影劑之組合物、方法及系統
AU2010224355B2 (en) Treatment of autoimmune diseases
PT1140078E (pt) Agentes de benzimidazole para problemas de vascularização
US20080076739A1 (en) Methods for treating arthritis using triheterocyclic compounds
EP2139889B1 (en) Amino-naphthyridine derivatives
JP2023182589A (ja) フェニルスルホンアミドを含む薬学的組成物、及びそれらの治療的適用
US8450318B2 (en) Method to treat infections using anti-infective agents
US11135209B2 (en) Compositions and methods for inhibiting protein kinases
SG185746A1 (en) Treatment of autoimmune diseases
BR112017000605B1 (pt) Forma policristalina do pró-fármaco de tenofovir, seu método de preparação e seu uso, e composição farmacêutica
US20180161290A1 (en) Dosage Regimen of Diaryl Sulfide Derivatives
FI60711C (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara 5,5-dimetyl-8-(p-fluorfenylalkyl)-10-hydroxi-2-(2-propynyl)-1,2,3,4-tetrahydro-5h-bensopyrano (4,3-c) pyridiner
WO2010099573A1 (en) Dioxolane norbornane / norbornene compounds suitable as antimicrobial agents to treat bacterial infections
HK40030015A (en) Compositions, methods and systems for the synthesis and use of imaging agents